Donald C Walker

US Patent:

7358331, Apr 15, 2008

Filed:

Jul 29, 2005

Appl. No.:

11/194115

Inventors:

Tamie J Chilcote - San Francisco CA, US
Jason Goldstein - Doraville GA, US
John P Anderson - San Francisco CA, US
Donald Walker - Pleasant Hill CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07K 14/00
C12P 21/06
C12N 15/00
A61K 38/00

US Classification:

530300, 530350, 435 691, 435440, 514 2, 514 12

Abstract:

The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

US Patent:

20090035217, Feb 5, 2009

Filed:

Feb 29, 2008

Appl. No.:

12/040739

Inventors:

Tamie J. Chilcote - San Francisco CA, US
Jason Goldstein - Burlingame CA, US
John P. Anderson - San Francisco CA, US
Donald Walker - Pleasant Hill CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 49/00
G01N 33/00
A01K 67/027
A61K 38/00
C12N 9/50
A61P 25/00
A61K 39/395
C12Q 1/02
C07K 16/18

US Classification:

424 91, 436 86, 800 3, 800 9, 435 29, 5303879, 5303873, 514 12, 4241391, 435219

Abstract:

The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

US Patent:

20130072663, Mar 21, 2013

Filed:

Sep 5, 2012

Appl. No.:

13/604441

Inventors:

Tamie J. Chilcote - San Francisco CA, US
Jason Goldstein - Burlingame CA, US
John P. Anderson - San Francisco CA, US
Donald Walker - Pleasant Hill CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07K 16/18

US Classification:

5303873, 5303879

Abstract:

The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

US Patent:

20180355028, Dec 13, 2018

Filed:

May 16, 2018

Appl. No.:

15/981008

Inventors:

- DUBLIN, IE
Jason Goldstein - Decatur GA, US
John P. Anderson - San Francisco CA, US
Donald Walker - Pleasant Hill CA, US

International Classification:

C07K 16/18
G01N 33/68
C12Q 1/6883
C12N 15/85

Abstract:

The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

US Patent:

20170204173, Jul 20, 2017

Filed:

Mar 22, 2017

Appl. No.:

15/466543

Inventors:

- Dublin, IE
Jason Goldstein - Decatur GA, US
John P. Anderson - San Francisco CA, US
Donald Walker - Pleasant Hill CA, US

International Classification:

C07K 16/18
G01N 33/68

Abstract:

The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.